Beruflich Dokumente
Kultur Dokumente
LOVASTATIN
AS A NATURALLY OCCURING
SUBSTANCE WITH
CHOLESTEROL LOWERING EFFECT
IN HERBAL MEDICINE CONTAINING
RED YEAST RICE
CONTENT
2
INTRODUCTION
EXPERIMENTAL
RESULT
DISCUSSION
CONCLUSION
INTRODUCTION
3
INTRODUCTION
4
1
2
INTRODUCTION
5
INTRODUCTION
6
Properties of Lovastatin
Generic names
Molecular formula
C27H36O5
Molecular weight
405.54 g/mol
Appearance
CAS
75330-75-5
Melting point
174.5C
Storage
2 8 C
temperature
Solubility
INTRODUCTION
7
Side effect of
lovastatin
INTRODUCTION
8
INTRODUCTION
9
WILDLIFE
WHOSE USE IS
PROHIBITED IN
TRADITIONAL
MEDICINE (as
listed in
Wildlife
PKA SEMINAR
Magnolia officinalis
(Reported to cause kidney toxicity)
Piper methysticum (kava-kava)
(Reported to cause liver toxicity)
Botanicals Known or
Suspected to contain or
maybe adulterated with
Aristolochic Acid
Papaver somniferum
Digitalis purpurea folium
Aristolochia spp.
(Aristolochia,Guan mu tong)
Akebia spp. (Akebia, Mu tong)
Javan Rhinoceros (Badak raya)
Scaly anteater or Pangolin
(Tenggiling)
EXPERIMENTAL
10
AIM OF STUDY
EXPERIMENTAL
11
No
25 samples of
herbal medicine
containing red
yeast rice + 5 raw
material of red
yeast rice from
different
manufacturer were
obtained from
National
Pharmaceutical
Control Bureau.
The sample is
actually collected
for surveillance
programmed.
Sample Number
Sample Name
2007110200
2008010221
2008050110
2008050111
2008050113
2008050114
2008050115
2008050116
2008050117
10
2008050118
11
2008050119
12
2008050120
Lipascor Capsule
13
2008050121
14
2008050122
15
2008050123
16
2008050124
17
2008050343
Levelcol Capsule
18
2008050358
19
2008050410
C'Care
EXPERIMENTAL
12
SCREENIN
G
(GCMS)
QUANTIFICATIO
N
(HPLC)
METHOD
VALIDATION
(HPLC)
EXPERIMENTAL-SCREENING
13
EXTRACTION
PROCESS
EXPERIMENTAL-SCREENING
14
INSTRUMENTATION
Chromatographic System for GC-MS
Equipment
Column
Oven temperature
100C
Run Time
32.5 min
Detector
Temperature
MS Quadrupole 150C , max 200C
MS Source 230C, max 250C
Injection Volume
1L
Mode
Splitless
Gas
Helium
Flow rate
1.0 ml/min
EXPERIMENTAL-SCREENING
15
STANDARD
SAMPLE
EXPERIMENTAL-SCREENING
16
Standard mass
spectrum
Principal ion at
m/z 159, 157,
64, 198, 172,
143, 105, 73
EXPERIMENTAL-SCREENING
17
Sample mass
spectrum
PKA SEMINAR 12 JULAI 2011
SCREENING RESULT
18
No
Sample Number
2007110200
Positive
2008010221
Positive
2008050110
Positive
2008050111
Positive
2008050113
Positive
2008050114
2008050115
Positive
2008050116
Positive
2008050117
Positive
10
2008050118
Positive
11
2008050119
Positive
12
2008050120
Lipascor Capsule
Positive
13
2008050121
Positive
14
2008050122
Positive
15
2008050123
Positive
16
2008050124
Positive
17
2008050343
Levelcol Capsule
Positive
18
2008050358
Positive
19
2008050410
C'Care
Positive
Sample Name
Result
Negative
QUANTIFICATION
19
QUANTIFICATION
20
PREPARATION OF STANDARD
1
2
3
PKA SEMINAR 12 JULAI 2011
PREPARATION OF SAMPLE
QUANTIFICATIONCALCULATION
21
Conc
Std
Final
weight volume
Calculation
1.
40 g/ml 4.120mg
100
2.
30 g/ml 3.088mg
100
3.
20 g/ml 2.100mg
100
4.
10 g/ml 2.108mg
200
5.
1 g/ml
100
Std wt (mg) x
1
x purity of std (%)
DF(ml)
4.120 mg x
100 ml
99.2
100
= 0.0408 mg/ml
QUANTIFICATION
22
INSTRUMENTATIO
N
Chromatographic System
Equipment
Mobile phase
Column
Oven temperature
45C
Run Time
6 min
Detector
238 UV DAD
Injection Volume
20L
Flow rate
1.8ml/min
Back Pressure
77kgf/cm2
QUANTIFICATION-RESULT
24
QUANTIFICATION-RESULT
25
QUANTIFICATION-RESULT
26
QUANTIFICATIONCALCULATION
27
0.6ml
0.2305g
Sample 1b
22.237ug/ml x 100ml x 1.2ml x 0.4821g = 9.63 mg/cap
1000
0.6ml
0.2227g
PKA SEMINAR 12 JULAI 2011
Average:
9.74mg/cap
SUMMARY OF RESULT -1
28
Bil
Sample
1.
22.468
9.56
1.98%
2.
7.105
1.75
0.35%
3.
7.117
1.74
9.163
2.71
14.397
3.25
4.
5.
6.
7.
8.
Amount of
lovastatin
(ug/ml)
Amount of
lovastatin
(mg/cap or tab)
Amount of
lovastatin (%w/w)
0.34%
0.45%
0.70%
14.449
2.16
0.70%
0.018
0.0029
0.0008%
SUMMARY OF RESULT - 2
29
Bil
Sample
9.
10.
Amount of
lovastatin
(ug/ml)
Amount of
lovastatin
(mg/cap or tab)
Amount of
lovastatin (%w/w)
10.145
2.38
0.38%
5.708
1.07
0.23%
11.
5.971
1.63
12.
Lipascor Capsule
15.772
4.74
13.
40.234
9.57
14.
5.179
1.27
15.
11.334
2.67
16.
4.787
0.74
0.26%
0.76%
1.86%
0.25%
0.56%
0.24%
SUMMARY OF RESULT - 3
30
Bil
Sample
Amount of
lovastatin
(ug/ml)
Amount of
lovastatin
(mg/cap or tab)
17.
Levelcol Capsule
20.9305
10.87
18.
6.771
1.19
19.
C'Care
1.628
0.40
20.
38.295
11.21
21.
2.624
0.74
.22
18.147
4.71
23.
11.708
3.21
24.
8.807
Amount of
lovastatin (%w/w)
2.05%
0.30%
0.07%
1.83%
0.33%
0.85%
0.54%
0.38%
SUMMARY OF RESULT - 4
31
Bil
25.
Sample
Amount of
lovastatin
(ug/ml)
27.189
26.
Raw Material 1
29.526
27.
Raw material 2
30.232
28.
Raw Material 3
56.923
29.
Raw Material 4
55.463
30.
Raw Material 5
12.294
Amount of
lovastatin
(mg/cap or tab)
7.53
Amount of
lovastatin (%w/w)
1.26%
1.45%
1.43%
2.77%
2.68%
0.60%
METHOD VALIDATION
32
Parameter
Acceptance criteria
System Suitability
Result
Symmetry = 1.079, Capacity
factor k, >1 , Theoretical
plate >7486
Specificity
Accuracy
9 determination at 3
concentration
Average recovery for each
concentration 100.3, 99.5,
97.7
33
System precision
Method precision
6 determination of sample
Mean = 2.655
%RSD = 2.903
DISCUSSION
34
CONCLUSION
35
DCA PAPER
36
REFERENCES
37
H.N Huang, Y.Y Hua et al, The Quantification of Monacolin K in Some Red Yeast Rice
from Fujian Province and the Comparison of the Other Product, Chem. Pharm. Bull.
2006, 54(5), p 687689.
Junxian Wang, Zongliang LU, Jiamin Chi et al, Multi-center Clinical Trial of the Serum
Lipid Lowering Effects of A Monascus Purpureus Rice (Red Yeast Rice) Preparation
From Traditional Chinese Medicine, Current Therapeutic Research Vol 58, No12,
December 1997.
Osama
Gheith,
Hussein
PKA
SEMINAR
12 JULAI
2011Sheashaa et al, Efficacy and safety of Monascus purpureus
Went rice in subjects with secondary hyperlipidemia, Clinical Exp Nephrology,
38